Literature DB >> 10691093

Hantavirus Dobrava infection with pulmonary manifestation.

R Mentel1, N Bordihn, U Wegner, H Wendel, B Niklasson.   

Abstract

Dobrava virus infection was diagnosed serologically by enzyme-linked immunosorbent and immunofluorescence assays. To determine which hantavirus serotype was involved, sera were analyzed by a focus reduction neutralization test. The clinical data indicated that only pulmonary manifestation was present. Our data support the presence of Dobrava virus infection outside the Balkan region. In conclusion, a previously healthy adult with unexplained pulmonary perfusion failure should be investigated for hantavirus infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10691093     DOI: 10.1007/s004300050104

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  4 in total

1.  Seroprevalence study in forestry workers of a non-endemic region in eastern Germany reveals infections by Tula and Dobrava-Belgrade hantaviruses.

Authors:  Marc Mertens; Jörg Hofmann; Rasa Petraityte-Burneikiene; Mario Ziller; Kestutis Sasnauskas; Robert Friedrich; Olaf Niederstrasser; Detlev H Krüger; Martin H Groschup; Eckhardt Petri; Sandra Werdermann; Rainer G Ulrich
Journal:  Med Microbiol Immunol       Date:  2011-05-25       Impact factor: 3.402

2.  Central European Dobrava Hantavirus isolate from a striped field mouse (Apodemus agrarius).

Authors:  Boris Klempa; Michal Stanko; Milan Labuda; Rainer Ulrich; Helga Meisel; Detlev H Krüger
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

Review 3.  Hantavirus infections in Greece--an update.

Authors:  A Papa; A Antoniadis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 4.  Complex evolution and epidemiology of Dobrava-Belgrade hantavirus: definition of genotypes and their characteristics.

Authors:  Boris Klempa; Tatjana Avsic-Zupanc; Jan Clement; Tamara K Dzagurova; Heikki Henttonen; Paul Heyman; Ferenc Jakab; Detlev H Kruger; Piet Maes; Anna Papa; Evgeniy A Tkachenko; Rainer G Ulrich; Olli Vapalahti; Antti Vaheri
Journal:  Arch Virol       Date:  2012-10-23       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.